智翔金泰跌2.17% 连亏4年3季2023年上市募34.7亿

Core Points - The stock of Zhixiang Jintai (688443.SH) closed at 28.82 yuan, with a decline of 2.17%, currently in a state of breaking issue [1] - Zhixiang Jintai was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on June 20, 2023, with an initial public offering (IPO) of 91.68 million shares at a price of 37.88 yuan per share [1] - The total amount raised from the IPO was 347.28 million yuan, with a net amount of 329.14 million yuan after deducting issuance costs, which was 68.86 million yuan less than the originally planned amount of 398 million yuan [1] - The company has reported losses for four consecutive years and three quarters, with net profits attributable to shareholders of -322 million yuan in 2021, -576 million yuan in 2022, -801 million yuan in 2023, and -797 million yuan in 2024 [2] - In the first three quarters of 2025, Zhixiang Jintai achieved revenue of 208 million yuan, a year-on-year increase of 1,562.05%, but still reported a net loss of -333 million yuan [2] Financial Summary - The total issuance costs for the IPO amounted to 18.14 million yuan, with underwriting fees of 16.50 million yuan [1] - The company’s cash flow from operating activities was -261 million yuan in the first three quarters of 2025 [2] - The company plans to use the raised funds for the construction and expansion of an antibody industrialization base, research and development of antibody drugs, and to supplement working capital [1]